The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay
The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. A cross-sectional...
Saved in:
| Published in | Human vaccines & immunotherapeutics Vol. 16; no. 9; pp. 2204 - 2214 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Taylor & Francis
01.09.2020
Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations.
A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP.
A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes.
The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP. |
|---|---|
| AbstractList | The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations.
A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP.
A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes.
The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP. Background The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. Methods A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP. Results A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19–5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03–4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes. Conclusions The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP. Background The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations. Methods A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP. Results A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19–5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03–4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes. Conclusions The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP. The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations.BACKGROUNDThe development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19 vaccine and willingness to pay (WTP) were assessed to provide insights into future demand forecasts and pricing considerations.A cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP.METHODSA cross-sectional survey was conducted from 3 to 12 April 2020. The health belief model (HBM) was used to assess predictors of the intent to receive the vaccine and the WTP.A total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes.RESULTSA total of 1,159 complete responses was received. The majority reported a definite intent to receive the vaccine (48.2%), followed by a probable intent (29.8%) and a possible intent (16.3%). Both items under the perceived benefits construct in the HBM, namely believe the vaccination decreases the chance of infection (OR = 2.51, 95% CI 1.19-5.26) and the vaccination makes them feel less worry (OR = 2.19, 95% CI 1.03-4.65), were found to have the highest significant odds of a definite intention to take the vaccine. The mean ± standard deviation (SD) for the amount that participants were willing to pay for a dose of COVID-19 vaccine was MYR$134.0 (SD±79.2) [US$30.66 ± 18.12]. Most of the participants were willing to pay an amount of MYR$100 [US$23] (28.9%) and MYR$50 [US$11.5] (27.2%) for the vaccine. The higher marginal WTP for the vaccine was influenced by no affordability barriers as well as by socio-economic factors, such as higher education levels, professional and managerial occupations and higher incomes.The findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP.CONCLUSIONSThe findings demonstrate the utility of HBM constructs in understanding COVID-19 vaccination intention and WTP. |
| Author | Wong, Pooi-Fong AbuBakar, Sazaly Lee, Hai Yen Wong, Li Ping Alias, Haridah |
| Author_xml | – sequence: 1 givenname: Li Ping surname: Wong fullname: Wong, Li Ping email: wonglp@ummc.edu.my organization: University of Malaya – sequence: 2 givenname: Haridah surname: Alias fullname: Alias, Haridah organization: University of Malaya – sequence: 3 givenname: Pooi-Fong orcidid: 0000-0002-0107-0532 surname: Wong fullname: Wong, Pooi-Fong organization: University of Malaya – sequence: 4 givenname: Hai Yen orcidid: 0000-0001-6322-6718 surname: Lee fullname: Lee, Hai Yen organization: University of Malaya – sequence: 5 givenname: Sazaly orcidid: 0000-0002-9267-1420 surname: AbuBakar fullname: AbuBakar, Sazaly organization: University of Malaya |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32730103$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk9vEzEQxVeoiJbSjwDykcsW27te7woJgcK_SJV6KYib5bXHiSvHDraTkm-Pt0kqygF8sTXz5vc08ntenfjgoapeEnxJcI_fUNK1jBF2STEtJT5gyocn1dlUrxlrf5w8vAk7rS5SusXlcEzbrntWnTaUN5jg5qz6dbMEtEmAgkG5PJcgXV6iEZwFg1ZBg0M5IJkSpITWEbRVOcQ06a3P4PPUjqDAbuGeMLv-Pv9YkwFtpVLWA5JeozvrnPULP0GKfi13L6qnRroEF4f7vPr2-dPN7Gt9df1lPvtwVasO41xT3OkBq04bo4ayOqZNI1tu9EhU3wyYEMMwjCC7XjFKtJbd2BKiBiMNh0E359V8z9VB3op1tCsZdyJIK-4LIS6EjNkqB0ISjI3qBt3ysdWajpp2vSlunChC-on1bs9ab8YVaFW2j9I9gj7ueLsUi7AVnLGG474AXh8AMfzcQMpiZZMC56SHsEmCtnTgfUN6VqSv_vR6MDl-XRG83QtUDClFMELZLLMNk7V1gmAxZUUcsyKmrIhDVso0-2v6aPC_uff7OetNiCt5F6LTIsudC9FE6ZVNovk34jeCz9XE |
| CitedBy_id | crossref_primary_10_3390_vaccines9121415 crossref_primary_10_4103_1995_7645_312513 crossref_primary_10_4103_1995_7645_312512 crossref_primary_10_3390_vaccines11091426 crossref_primary_10_3390_vaccines11101558 crossref_primary_10_3390_ijerph192013420 crossref_primary_10_4081_jphr_2021_2273 crossref_primary_10_1186_s12913_022_08379_3 crossref_primary_10_1080_13669877_2021_1958044 crossref_primary_10_1007_s10198_022_01437_x crossref_primary_10_3390_jpm12010111 crossref_primary_10_1007_s00520_022_07238_5 crossref_primary_10_3390_vaccines10040544 crossref_primary_10_3390_ijerph19031521 crossref_primary_10_21926_obm_neurobiol_2302166 crossref_primary_10_1108_ITP_06_2023_0622 crossref_primary_10_3389_fcomm_2022_876656 crossref_primary_10_1186_s12889_024_21027_1 crossref_primary_10_3390_vaccines10050697 crossref_primary_10_1371_journal_pgph_0000742 crossref_primary_10_1080_07359683_2024_2352187 crossref_primary_10_3389_fpsyg_2022_879300 crossref_primary_10_3390_ijerph19031898 crossref_primary_10_1371_journal_pone_0293350 crossref_primary_10_1080_21645515_2021_1989914 crossref_primary_10_1177_20499361231213226 crossref_primary_10_3389_fpubh_2023_1036110 crossref_primary_10_1007_s12144_023_04953_y crossref_primary_10_3390_healthcare9111530 crossref_primary_10_1017_S0950268821002314 crossref_primary_10_1080_13675567_2021_1974365 crossref_primary_10_1108_JSOCM_04_2021_0085 crossref_primary_10_7759_cureus_28326 crossref_primary_10_1080_21645515_2022_2146964 crossref_primary_10_1186_s12889_022_14225_2 crossref_primary_10_1371_journal_pone_0301383 crossref_primary_10_1177_20503121231159750 crossref_primary_10_1136_bmjgh_2022_009250 crossref_primary_10_2196_24673 crossref_primary_10_1038_s41598_022_05915_3 crossref_primary_10_3390_ijerph19031305 crossref_primary_10_1080_21645515_2022_2076523 crossref_primary_10_2147_JMDH_S306654 crossref_primary_10_3390_vaccines10071159 crossref_primary_10_3934_publichealth_2022012 crossref_primary_10_1080_21645515_2021_1981087 crossref_primary_10_1177_21582440221093046 crossref_primary_10_1080_21645515_2020_1853449 crossref_primary_10_3390_cancers13246294 crossref_primary_10_1016_j_socscimed_2021_114561 crossref_primary_10_1093_pubmed_fdab401 crossref_primary_10_36681_tused_2023_032 crossref_primary_10_1016_j_ijdrr_2022_103056 crossref_primary_10_1111_aphw_12262 crossref_primary_10_1371_journal_pone_0270349 crossref_primary_10_1080_07448481_2023_2258414 crossref_primary_10_1080_21645515_2021_1896907 crossref_primary_10_1186_s12889_022_13755_z crossref_primary_10_1371_journal_pone_0286924 crossref_primary_10_3390_idr14060101 crossref_primary_10_3390_vaccines10081183 crossref_primary_10_34172_jech_2022_11 crossref_primary_10_1016_j_puhe_2023_01_014 crossref_primary_10_1186_s12889_022_14029_4 crossref_primary_10_1007_s10389_022_01757_5 crossref_primary_10_1080_21645515_2021_1989918 crossref_primary_10_1016_j_sjbs_2021_11_058 crossref_primary_10_1155_2022_2313367 crossref_primary_10_1136_bmjgh_2020_004450 crossref_primary_10_1007_s13412_023_00887_w crossref_primary_10_3390_vaccines11101516 crossref_primary_10_3390_ijerph191610185 crossref_primary_10_52589_IJPHP_BMM5SJBY crossref_primary_10_4103_jehp_jehp_1480_22 crossref_primary_10_3390_vaccines11020421 crossref_primary_10_51867_ajernet_5_4_7 crossref_primary_10_3390_healthcare10030582 crossref_primary_10_1038_s41598_022_23825_2 crossref_primary_10_1136_bmjopen_2021_057322 crossref_primary_10_1080_21645515_2021_2009290 crossref_primary_10_1371_journal_pone_0256110 crossref_primary_10_1515_openhe_2022_0010 crossref_primary_10_31832_smj_1085235 crossref_primary_10_3390_vaccines10030427 crossref_primary_10_1080_21645515_2021_1991183 crossref_primary_10_3390_su131911024 crossref_primary_10_5812_ipmn_131019 crossref_primary_10_3390_vaccines9040379 crossref_primary_10_1186_s12879_021_06406_y crossref_primary_10_1371_journal_pone_0268587 crossref_primary_10_3389_fpsyg_2022_876116 crossref_primary_10_7759_cureus_72131 crossref_primary_10_3390_vaccines10071095 crossref_primary_10_3390_vaccines9090994 crossref_primary_10_2196_45051 crossref_primary_10_1007_s12144_025_07281_5 crossref_primary_10_3390_vaccines10071099 crossref_primary_10_1371_journal_pone_0270768 crossref_primary_10_1136_bmjopen_2021_056345 crossref_primary_10_24171_j_phrp_2021_0085 crossref_primary_10_3390_foods13091424 crossref_primary_10_1016_j_vhri_2021_10_004 crossref_primary_10_1097_JOM_0000000000003232 crossref_primary_10_1108_JSTPM_09_2021_0137 crossref_primary_10_1080_10810730_2023_2282036 crossref_primary_10_1016_j_vaccine_2022_04_077 crossref_primary_10_1038_s41598_024_76437_3 crossref_primary_10_3389_fpubh_2024_1340614 crossref_primary_10_3390_vaccines11020403 crossref_primary_10_3390_vaccines9090967 crossref_primary_10_1159_000514636 crossref_primary_10_1186_s12982_024_00236_4 crossref_primary_10_2147_JMDH_S353594 crossref_primary_10_4103_jehp_jehp_647_21 crossref_primary_10_3389_fpubh_2022_1044193 crossref_primary_10_1515_ohe_2023_0027 crossref_primary_10_1007_s41669_024_00494_7 crossref_primary_10_1080_21645515_2021_2000262 crossref_primary_10_1186_s12939_025_02428_z crossref_primary_10_3389_fmed_2021_783982 crossref_primary_10_1080_21645515_2024_2313860 crossref_primary_10_1016_j_puhip_2023_100359 crossref_primary_10_5812_jhealthscope_134323 crossref_primary_10_1111_jan_15002 crossref_primary_10_1016_j_lanwpc_2022_100534 crossref_primary_10_21272_hem_2022_1_06 crossref_primary_10_3390_vaccines10071061 crossref_primary_10_1080_21645515_2021_1942713 crossref_primary_10_2196_26895 crossref_primary_10_3390_ijerph182312450 crossref_primary_10_3389_fpsyg_2022_808338 crossref_primary_10_3389_fpsyg_2022_916960 crossref_primary_10_3390_vaccines9040380 crossref_primary_10_1007_s40258_021_00687_9 crossref_primary_10_1080_10410236_2022_2028469 crossref_primary_10_3389_fpubh_2021_711066 crossref_primary_10_3390_ijerph191912892 crossref_primary_10_1111_deve_12332 crossref_primary_10_1177_2333794X211048738 crossref_primary_10_3389_fpsyg_2022_925675 crossref_primary_10_4103_jcsr_jcsr_38_21 crossref_primary_10_1016_j_tmaid_2021_102059 crossref_primary_10_1016_j_tourman_2021_104405 crossref_primary_10_1080_14760584_2021_1969917 crossref_primary_10_1177_10755470221101067 crossref_primary_10_2139_ssrn_3935659 crossref_primary_10_1371_journal_pone_0282520 crossref_primary_10_47836_mjmhs_18_5_12 crossref_primary_10_1016_j_ijnurstu_2020_103854 crossref_primary_10_1080_21645515_2022_2078634 crossref_primary_10_3389_fpsyg_2021_676521 crossref_primary_10_3390_joitmc8030114 crossref_primary_10_1371_journal_pone_0268775 crossref_primary_10_1016_j_heliyon_2023_e18079 crossref_primary_10_3389_fpsyg_2022_1025638 crossref_primary_10_1177_23333928221106269 crossref_primary_10_4103_npmj_npmj_332_22 crossref_primary_10_3389_fpubh_2024_1420270 crossref_primary_10_1186_s12889_023_15409_0 crossref_primary_10_1080_21645515_2023_2283315 crossref_primary_10_2147_PPA_S362264 crossref_primary_10_3389_ijph_2023_1605539 crossref_primary_10_3390_vaccines9080864 crossref_primary_10_1007_s10935_022_00684_1 crossref_primary_10_3390_vaccines9030246 crossref_primary_10_1186_s12889_024_18797_z crossref_primary_10_1016_j_vaccine_2023_02_026 crossref_primary_10_32895_UMP_MPR_7_1_10 crossref_primary_10_1051_bioconf_202515403009 crossref_primary_10_1016_j_vaccine_2021_09_038 crossref_primary_10_1177_23743735231183673 crossref_primary_10_3390_vaccines11040803 crossref_primary_10_3390_vaccines9010062 crossref_primary_10_1186_s12889_021_11880_9 crossref_primary_10_1371_journal_pone_0303172 crossref_primary_10_2147_PPA_S362131 crossref_primary_10_30621_jbachs_966367 crossref_primary_10_2147_RMHP_S315043 crossref_primary_10_3389_fpubh_2021_715931 crossref_primary_10_2196_67650 crossref_primary_10_2139_ssrn_4372210 crossref_primary_10_3390_vaccines9080876 crossref_primary_10_1016_j_socscimed_2021_114273 crossref_primary_10_1080_10646175_2022_2106168 crossref_primary_10_1080_19325037_2022_2071362 crossref_primary_10_3390_vaccines9080873 crossref_primary_10_1002_casp_2542 crossref_primary_10_1080_00222216_2022_2158764 crossref_primary_10_1016_j_vaccine_2021_06_044 crossref_primary_10_1177_00469580221082787 crossref_primary_10_1080_21645515_2021_1938921 crossref_primary_10_1186_s12889_022_14438_5 crossref_primary_10_3390_vaccines10101640 crossref_primary_10_1007_s43545_024_00893_x crossref_primary_10_3390_vaccines10010077 crossref_primary_10_2139_ssrn_3803323 crossref_primary_10_12688_wellcomeopenres_17517_1 crossref_primary_10_3390_vaccines10081231 crossref_primary_10_3390_vaccines9080847 crossref_primary_10_4103_jdrysruhs_jdrysruhs_159_22 crossref_primary_10_1080_07359683_2021_1987030 crossref_primary_10_1007_s11077_022_09481_3 crossref_primary_10_1080_21645515_2023_2179788 crossref_primary_10_3390_vaccines10060893 crossref_primary_10_1371_journal_pone_0260821 crossref_primary_10_3390_vaccines10081356 crossref_primary_10_1080_21645515_2022_2063629 crossref_primary_10_1186_s12879_022_07269_7 crossref_primary_10_2147_RMHP_S352584 crossref_primary_10_3390_bs13080693 crossref_primary_10_3390_vaccines9030275 crossref_primary_10_1080_10641734_2022_2079025 crossref_primary_10_1080_14737167_2022_2045957 crossref_primary_10_1186_s12889_022_13602_1 crossref_primary_10_1016_j_amepre_2021_01_008 crossref_primary_10_1016_j_rie_2024_100986 crossref_primary_10_1016_j_tmp_2022_100981 crossref_primary_10_1017_dmp_2022_257 crossref_primary_10_4102_hsag_v28i0_2265 crossref_primary_10_1080_19325037_2021_1955231 crossref_primary_10_3390_vaccines11040816 crossref_primary_10_1016_j_paid_2021_110696 crossref_primary_10_3389_fpubh_2022_957721 crossref_primary_10_1108_LHT_07_2023_0309 crossref_primary_10_3389_fmed_2021_756985 crossref_primary_10_3389_fpubh_2021_793533 crossref_primary_10_3390_vaccines11050973 crossref_primary_10_1177_00332941231219644 crossref_primary_10_1016_j_vaccine_2021_07_056 crossref_primary_10_1186_s12889_024_20274_6 crossref_primary_10_12688_f1000research_123583_3 crossref_primary_10_1371_journal_pone_0269942 crossref_primary_10_12688_f1000research_123583_2 crossref_primary_10_1371_journal_pone_0247997 crossref_primary_10_12688_f1000research_123583_1 crossref_primary_10_1080_10410236_2022_2149065 crossref_primary_10_1371_journal_pone_0289678 crossref_primary_10_1080_10410236_2023_2204583 crossref_primary_10_2147_RMHP_S432153 crossref_primary_10_1108_JFM_02_2023_0022 crossref_primary_10_3389_fpsyg_2021_729803 crossref_primary_10_3390_ijerph191811729 crossref_primary_10_1007_s40258_021_00644_6 crossref_primary_10_1016_j_vaccine_2021_06_014 crossref_primary_10_3390_vaccines10040627 crossref_primary_10_1007_s40258_023_00815_7 crossref_primary_10_1080_21645515_2023_2177068 crossref_primary_10_3390_vaccines9070745 crossref_primary_10_57127_kpd_26024438_1274631 crossref_primary_10_1016_j_vaccine_2020_12_009 crossref_primary_10_3390_vaccines9030292 crossref_primary_10_2147_CEOR_S361199 crossref_primary_10_3390_ijerph18116141 crossref_primary_10_3390_vaccines9030297 crossref_primary_10_2147_PPA_S312806 crossref_primary_10_1007_s13187_023_02323_7 crossref_primary_10_1080_21645515_2021_2024064 crossref_primary_10_3390_vaccines10040609 crossref_primary_10_1016_j_vaccine_2023_01_029 crossref_primary_10_1371_journal_pone_0253499 crossref_primary_10_3389_fpubh_2022_917242 crossref_primary_10_46754_umtjur_v6i1_456 crossref_primary_10_2174_0118749445305521240516051327 crossref_primary_10_1016_j_ssmph_2021_100824 crossref_primary_10_1017_dmp_2023_11 crossref_primary_10_1080_21645515_2024_2361503 crossref_primary_10_1186_s12879_022_07191_y crossref_primary_10_2478_crdj_2022_0009 crossref_primary_10_1016_j_ehb_2022_101135 crossref_primary_10_1002_hpm_3582 crossref_primary_10_1080_10810730_2022_2160526 crossref_primary_10_1186_s12889_023_17497_4 crossref_primary_10_1080_21645515_2020_1819741 crossref_primary_10_2147_RMHP_S351794 crossref_primary_10_3390_vaccines10101605 crossref_primary_10_3390_vaccines9010016 crossref_primary_10_2196_46624 crossref_primary_10_1371_journal_pone_0290412 crossref_primary_10_3389_fcomm_2022_1094850 crossref_primary_10_1371_journal_pone_0305659 crossref_primary_10_1093_abm_kaab091 crossref_primary_10_1016_j_vaccine_2022_01_061 crossref_primary_10_3390_vaccines10050671 crossref_primary_10_3390_vaccines9030191 crossref_primary_10_61186_ioh_20_1_16 crossref_primary_10_1186_s41182_021_00337_9 crossref_primary_10_1111_jep_13722 crossref_primary_10_3389_fpsyg_2021_619145 crossref_primary_10_3389_fpubh_2022_938067 crossref_primary_10_3390_vaccines9020160 crossref_primary_10_3389_fpsyg_2021_783374 crossref_primary_10_4236_ojim_2021_114017 crossref_primary_10_7717_peerj_12887 crossref_primary_10_7759_cureus_35673 crossref_primary_10_1007_s12144_024_05647_9 crossref_primary_10_1111_nuf_12676 crossref_primary_10_1093_tbm_ibaa146 crossref_primary_10_1177_00953997211073459 crossref_primary_10_1371_journal_pntd_0010103 crossref_primary_10_3390_vaccines9070783 crossref_primary_10_1016_j_jbusres_2022_113480 crossref_primary_10_3389_fpubh_2024_1395941 crossref_primary_10_1371_journal_pone_0268926 crossref_primary_10_1080_08974438_2025_2465291 crossref_primary_10_1080_08870446_2023_2190761 crossref_primary_10_1080_21645515_2021_1981726 crossref_primary_10_3390_ijerph19159261 crossref_primary_10_3390_vaccines9060600 crossref_primary_10_1186_s12889_023_15203_y crossref_primary_10_1186_s12889_022_13355_x crossref_primary_10_3390_ijerph18179342 crossref_primary_10_1080_21645515_2021_1919453 crossref_primary_10_1002_nop2_1954 crossref_primary_10_3389_fpubh_2021_777565 crossref_primary_10_1111_risa_14220 crossref_primary_10_3389_fviro_2023_1065991 crossref_primary_10_1186_s12889_021_10816_7 crossref_primary_10_3390_vaccines9101135 crossref_primary_10_3390_ijerph19116682 crossref_primary_10_1080_02522667_2022_2118973 crossref_primary_10_5195_ijms_2022_1192 crossref_primary_10_1080_21645515_2023_2168936 crossref_primary_10_1108_IJPHM_12_2021_0117 crossref_primary_10_1186_s12889_024_18028_5 crossref_primary_10_1016_j_vaccine_2022_05_029 crossref_primary_10_1016_j_vaccine_2021_12_020 crossref_primary_10_3390_vaccines10010110 crossref_primary_10_1186_s41937_023_00116_9 crossref_primary_10_3928_24748307_20240607_01 crossref_primary_10_1016_j_jvacx_2022_100164 crossref_primary_10_1136_bmjopen_2022_061732 crossref_primary_10_3390_vaccines10122026 crossref_primary_10_1371_journal_pone_0287589 crossref_primary_10_1111_tmi_13666 crossref_primary_10_1016_j_tele_2024_102173 crossref_primary_10_1093_jphsr_rmab060 crossref_primary_10_1016_j_jvacx_2023_100324 crossref_primary_10_2174_26669587_v2_e221117_2022_20 crossref_primary_10_2196_28118 crossref_primary_10_2196_29329 crossref_primary_10_1080_21645515_2021_1909327 crossref_primary_10_1080_01490400_2023_2267039 crossref_primary_10_1080_21645515_2021_1954441 crossref_primary_10_3390_ijerph18063247 crossref_primary_10_3390_vaccines10070987 crossref_primary_10_1111_bjhp_12606 crossref_primary_10_3390_vaccines9020129 crossref_primary_10_1016_j_jvacx_2024_100515 crossref_primary_10_1177_15245004221134208 crossref_primary_10_3389_fpsyg_2022_772870 crossref_primary_10_3390_vaccines10010129 crossref_primary_10_1016_j_marpol_2021_104586 crossref_primary_10_1002_hec_4690 crossref_primary_10_1016_j_sapharm_2022_09_003 crossref_primary_10_12688_f1000research_135262_3 crossref_primary_10_1177_01600176221132231 crossref_primary_10_12688_f1000research_135262_2 crossref_primary_10_1080_08974438_2022_2035881 crossref_primary_10_1136_bmjopen_2022_070551 crossref_primary_10_12688_f1000research_135262_1 crossref_primary_10_3390_healthcare9070781 crossref_primary_10_1111_jocn_16958 crossref_primary_10_1136_bmjopen_2023_079783 crossref_primary_10_3389_fpubh_2022_854146 crossref_primary_10_1016_j_vaccine_2022_07_059 crossref_primary_10_1080_21645515_2023_2270325 crossref_primary_10_3389_fpsyg_2022_936917 crossref_primary_10_1002_jcop_22652 crossref_primary_10_3390_vaccines11010185 crossref_primary_10_1111_hex_13274 crossref_primary_10_3390_vaccines10050820 crossref_primary_10_29333_ejecs_1383 crossref_primary_10_3390_ijerph19052707 crossref_primary_10_1080_21645515_2022_2129929 crossref_primary_10_1136_bmjopen_2020_048172 crossref_primary_10_3390_vaccines10010011 crossref_primary_10_1080_19325037_2023_2187486 crossref_primary_10_1080_21645515_2021_1899732 crossref_primary_10_3389_fpsyg_2025_1481147 crossref_primary_10_1371_journal_pone_0250495 crossref_primary_10_1371_journal_pone_0276763 crossref_primary_10_3390_vaccines9101203 crossref_primary_10_3389_fmed_2022_890503 crossref_primary_10_2196_50181 crossref_primary_10_3390_ijerph19073887 crossref_primary_10_3389_fphar_2022_1013485 crossref_primary_10_1016_j_pedn_2024_03_017 crossref_primary_10_29333_ejgm_12413 crossref_primary_10_31965_infokes_Vol20_Iss1_588 crossref_primary_10_1007_s10389_021_01677_w crossref_primary_10_3390_healthcare11040583 crossref_primary_10_1080_13548506_2023_2181977 crossref_primary_10_3389_fpubh_2022_870880 crossref_primary_10_32481_djph_2021_12_015 crossref_primary_10_1016_j_imu_2022_101107 crossref_primary_10_3390_vaccines9091044 crossref_primary_10_3390_ijerph182212035 crossref_primary_10_3390_vaccines9111248 crossref_primary_10_52547_jech_8_3_223 crossref_primary_10_3390_vaccines10091488 crossref_primary_10_3389_fpubh_2021_698111 crossref_primary_10_3389_fpubh_2022_1030695 crossref_primary_10_3389_fpsyg_2022_968902 crossref_primary_10_1080_07359683_2021_1987020 crossref_primary_10_1080_13548506_2022_2058031 crossref_primary_10_1093_jphsr_rmab012 crossref_primary_10_1080_21645515_2023_2165383 crossref_primary_10_30935_ojcmt_13783 crossref_primary_10_1016_j_heliyon_2024_e26043 crossref_primary_10_1016_j_jpsychires_2023_10_014 crossref_primary_10_4103_ijnmr_ijnmr_337_21 crossref_primary_10_2139_ssrn_4057234 crossref_primary_10_3389_fpubh_2020_608852 crossref_primary_10_3390_vaccines10050806 crossref_primary_10_1080_21645515_2021_2016008 crossref_primary_10_3390_ijerph182111192 crossref_primary_10_1080_19325037_2024_2338449 crossref_primary_10_3389_fpubh_2023_1043485 crossref_primary_10_1371_journal_pone_0309623 crossref_primary_10_1016_j_socscimed_2022_115403 crossref_primary_10_2147_JMDH_S380171 crossref_primary_10_2147_RMHP_S311074 crossref_primary_10_1007_s11096_021_01344_w crossref_primary_10_1371_journal_pone_0266724 crossref_primary_10_1007_s12529_024_10269_3 crossref_primary_10_12688_f1000research_126560_1 crossref_primary_10_3390_vaccines9050515 crossref_primary_10_3390_vaccines9101100 crossref_primary_10_52547_ijhehp_10_3_299 crossref_primary_10_1080_21645515_2021_2000817 crossref_primary_10_3389_fpubh_2023_1085197 crossref_primary_10_1108_JEIM_06_2021_0267 crossref_primary_10_1177_08901171211045038 crossref_primary_10_47836_mjmhs_19_4_13 crossref_primary_10_1080_21645515_2023_2166321 crossref_primary_10_3390_vaccines9060548 crossref_primary_10_1016_j_vaccine_2024_126225 crossref_primary_10_1080_21645515_2023_2166323 crossref_primary_10_3389_fpubh_2025_1508369 crossref_primary_10_1080_21645515_2021_1933687 crossref_primary_10_1017_dmp_2021_262 crossref_primary_10_1016_j_vaccine_2021_12_059 crossref_primary_10_14710_nmjn_v13i1_47694 crossref_primary_10_3390_vaccines9070696 crossref_primary_10_1080_10810730_2023_2191225 crossref_primary_10_4103_jehp_jehp_642_21 crossref_primary_10_3390_tropicalmed7110331 crossref_primary_10_1007_s43076_022_00170_x crossref_primary_10_2139_ssrn_3866284 crossref_primary_10_1007_s43076_021_00099_7 crossref_primary_10_1080_21645515_2024_2318133 crossref_primary_10_1136_bmjopen_2022_068668 crossref_primary_10_3390_ijerph19169914 crossref_primary_10_1016_j_sciaf_2022_e01334 crossref_primary_10_1080_21645515_2023_2238513 crossref_primary_10_1016_j_pec_2021_09_023 crossref_primary_10_1177_23333928221083057 crossref_primary_10_1186_s12889_022_12969_5 crossref_primary_10_3390_ecm1040039 crossref_primary_10_3390_ijerph19116816 crossref_primary_10_3390_vaccines9060682 crossref_primary_10_1007_s12119_022_10017_3 crossref_primary_10_3389_fpsyg_2021_694151 crossref_primary_10_11616_asbi_1162554 crossref_primary_10_1136_bmjopen_2020_048025 crossref_primary_10_3390_vaccines9111323 crossref_primary_10_1080_13548506_2022_2105913 crossref_primary_10_1016_j_vacune_2022_08_003 crossref_primary_10_2147_IDR_S419952 crossref_primary_10_1080_14760584_2021_1964963 crossref_primary_10_1177_00469580231168494 crossref_primary_10_1080_21645515_2022_2091899 crossref_primary_10_1080_21645515_2022_2054260 crossref_primary_10_2174_2772434417666220907151635 crossref_primary_10_3390_healthcare11081140 crossref_primary_10_1016_j_vaccine_2022_04_030 crossref_primary_10_1080_00223980_2022_2101419 crossref_primary_10_1080_21645515_2022_2056400 crossref_primary_10_1016_j_ijans_2022_100401 crossref_primary_10_2139_ssrn_3905783 crossref_primary_10_1186_s12889_025_21610_0 crossref_primary_10_1080_09537325_2021_1988919 crossref_primary_10_3390_vaccines9121393 crossref_primary_10_3390_vaccines9121398 crossref_primary_10_1371_journal_pone_0319798 crossref_primary_10_1371_journal_pone_0266925 crossref_primary_10_1186_s12889_023_17532_4 crossref_primary_10_1016_j_sapharm_2020_12_012 crossref_primary_10_1016_j_ypmed_2021_106694 crossref_primary_10_3390_vaccines9060585 crossref_primary_10_1016_j_puhe_2021_07_035 crossref_primary_10_1111_aphw_12304 crossref_primary_10_1016_j_tele_2021_101765 crossref_primary_10_1080_00909882_2024_2385351 crossref_primary_10_3390_vaccines9111225 crossref_primary_10_1038_s43856_024_00628_2 crossref_primary_10_1016_j_jvacx_2021_100091 crossref_primary_10_5812_semj_127210 crossref_primary_10_3389_fpsyg_2022_963560 crossref_primary_10_1093_heapro_daac078 crossref_primary_10_1080_19371918_2024_2323140 crossref_primary_10_3389_fpsyg_2023_1080097 crossref_primary_10_1038_s41598_024_58603_9 crossref_primary_10_3390_ijerph181910483 crossref_primary_10_1007_s10900_022_01093_5 crossref_primary_10_1371_journal_pone_0274972 crossref_primary_10_3390_ijerph20064796 crossref_primary_10_1016_j_eclinm_2021_101113 crossref_primary_10_3390_vaccines10091533 crossref_primary_10_1017_ice_2021_201 crossref_primary_10_1186_s12889_022_13236_3 crossref_primary_10_12677_NS_2021_103026 crossref_primary_10_1016_j_vacun_2021_08_002 crossref_primary_10_4103_1995_7645_351769 crossref_primary_10_1080_10911359_2021_1896409 crossref_primary_10_1038_s41598_024_71857_7 crossref_primary_10_3390_vaccines11061092 crossref_primary_10_1016_j_jvacx_2023_100301 crossref_primary_10_3389_fpubh_2021_626852 crossref_primary_10_1016_j_tranpol_2021_08_002 crossref_primary_10_1080_21645515_2021_1930473 crossref_primary_10_3390_vaccines10060917 crossref_primary_10_2147_IDR_S308446 crossref_primary_10_1136_bmjopen_2020_048586 crossref_primary_10_3389_fpubh_2022_882909 crossref_primary_10_1080_15323269_2022_2088203 crossref_primary_10_1111_saje_12311 crossref_primary_10_3389_fpubh_2021_760388 crossref_primary_10_3390_vaccines9050445 crossref_primary_10_20473_jmtt_v15i2_36335 crossref_primary_10_1016_j_tmaid_2022_102409 crossref_primary_10_3390_vaccines9050443 crossref_primary_10_1186_s41256_021_00202_6 crossref_primary_10_1080_07448481_2022_2103381 crossref_primary_10_1007_s12144_021_02498_6 crossref_primary_10_1108_GKMC_12_2021_0191 crossref_primary_10_1177_20552076231185430 crossref_primary_10_4103_shb_shb_52_22 crossref_primary_10_1080_21645515_2021_1985355 crossref_primary_10_3390_ijerph20054529 crossref_primary_10_1080_23311975_2022_2031682 crossref_primary_10_1016_j_techsoc_2021_101830 crossref_primary_10_1108_NFS_08_2022_0258 crossref_primary_10_3389_fcomm_2021_780415 crossref_primary_10_1080_07853890_2022_2114606 crossref_primary_10_1590_0037_8682_0713_2020 crossref_primary_10_1155_2023_6915125 crossref_primary_10_1080_21645515_2022_2099166 crossref_primary_10_29333_ejmets_11890 crossref_primary_10_18006_2022_10_3__544_553 crossref_primary_10_1371_journal_pone_0269059 crossref_primary_10_1093_tbm_ibab102 crossref_primary_10_3389_fcomm_2021_638031 crossref_primary_10_3390_healthcare11040601 crossref_primary_10_1177_01939459241230383 crossref_primary_10_1177_10541373221118149 crossref_primary_10_3390_ijerph19095245 crossref_primary_10_3390_vaccines9111304 crossref_primary_10_1080_10410236_2022_2056981 crossref_primary_10_1080_07359683_2023_2193076 crossref_primary_10_2298_PSI220728001L crossref_primary_10_3390_vaccines9121461 crossref_primary_10_2196_26125 crossref_primary_10_1080_21645515_2021_2011651 crossref_primary_10_1177_21501319231159814 crossref_primary_10_1177_23779608231196662 crossref_primary_10_1007_s10995_023_03752_y |
| Cites_doi | 10.1371/currents.outbreaks.9e239605f4d320c6ad27ce2aea5aaad2 10.1377/hlthaff.2011.0396 10.1080/10410236.2017.1384353 10.1016/j.socec.2012.05.001 10.1177/109019817400200407 10.1371/journal.pone.0170550 10.1037/0278-6133.26.2.136 10.1098/rsif.2016.0820 10.1186/s12962-018-0163-2 10.1016/j.ebiom.2016.08.042 10.1007/s11747-019-00666-6 10.1016/j.vaccine.2011.10.030 10.1371/journal.pone.0215125 10.1002/jmv.25678 10.1002/9781118548387 10.1086/341419 10.1007/s10198-008-0124-3 10.3390/ijerph7030853 |
| ContentType | Journal Article |
| Copyright | 2020 Taylor & Francis Group, LLC 2020 2020 Taylor & Francis Group, LLC 2020 Taylor & Francis |
| Copyright_xml | – notice: 2020 Taylor & Francis Group, LLC 2020 – notice: 2020 Taylor & Francis Group, LLC 2020 Taylor & Francis |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1080/21645515.2020.1790279 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | L. P. WONG ET AL |
| EISSN | 2164-554X |
| EndPage | 2214 |
| ExternalDocumentID | oai_doaj_org_article_a100fc69d47b4dd2bd268fa4771c118d PMC7553708 32730103 10_1080_21645515_2020_1790279 1790279 |
| Genre | Research Article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Malaysia |
| GeographicLocations_xml | – name: Malaysia |
| GroupedDBID | --- 00X 0YH 30N 4.4 53G AALUX ABEIZ ABUPF ACENM ACGFS ADBBV ADCVX AECIN AENEX AEXWM AGYJP AIJEM ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS ARJSQ BABNJ BAWUL BLEHA BOHLJ CCCUG DGEBU DIK EBS H13 HYE IPNFZ KYCEM LJTGL M4Z O9- OK1 RIG RPM TDBHL TFL TFW TTHFI AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM GROUPED_DOAJ |
| ID | FETCH-LOGICAL-c600t-206d90c6dffc90800233a47fdb1c839011f50ebea68c521dda6b411c9faf7e9d3 |
| IEDL.DBID | DOA |
| ISSN | 2164-5515 2164-554X |
| IngestDate | Wed Aug 27 01:24:07 EDT 2025 Thu Aug 21 14:18:21 EDT 2025 Thu Jul 10 18:19:59 EDT 2025 Mon Jul 21 05:56:39 EDT 2025 Tue Jul 01 02:46:12 EDT 2025 Thu Apr 24 23:07:30 EDT 2025 Wed Dec 25 09:03:56 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | willingness to pay Malaysia health belief model COVID-19 vaccination intention |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c600t-206d90c6dffc90800233a47fdb1c839011f50ebea68c521dda6b411c9faf7e9d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-0107-0532 0000-0001-6322-6718 0000-0002-9267-1420 |
| OpenAccessLink | https://doaj.org/article/a100fc69d47b4dd2bd268fa4771c118d |
| PMID | 32730103 |
| PQID | 2429783185 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7553708 informaworld_taylorfrancis_310_1080_21645515_2020_1790279 crossref_citationtrail_10_1080_21645515_2020_1790279 proquest_miscellaneous_2429783185 crossref_primary_10_1080_21645515_2020_1790279 doaj_primary_oai_doaj_org_article_a100fc69d47b4dd2bd268fa4771c118d pubmed_primary_32730103 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-09-01 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Human vaccines & immunotherapeutics |
| PublicationTitleAlternate | Hum Vaccin Immunother |
| PublicationYear | 2020 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | cit0012 cit0010 Zainudin EN (cit0017) 2018; 17 cit0019 Champion V (cit0013) 2008; 4 cit0018 cit0015 cit0016 cit0014 cit0022 cit0001 cit0023 cit0020 cit0021 Iwashita Y (cit0011) 2010; 57 cit0008 cit0009 Glanz K (cit0005) 2008 cit0006 cit0007 cit0004 cit0002 cit0024 cit0003 cit0025 |
| References_xml | – ident: cit0023 doi: 10.1371/currents.outbreaks.9e239605f4d320c6ad27ce2aea5aaad2 – ident: cit0003 doi: 10.1377/hlthaff.2011.0396 – volume-title: Health behavior and health education: theory, research, and practice year: 2008 ident: cit0005 – ident: cit0018 doi: 10.1080/10410236.2017.1384353 – ident: cit0002 – ident: cit0009 doi: 10.1016/j.socec.2012.05.001 – ident: cit0021 – ident: cit0012 doi: 10.1177/109019817400200407 – volume: 4 volume-title: Health behavior and health education year: 2008 ident: cit0013 – ident: cit0016 doi: 10.1371/journal.pone.0170550 – ident: cit0006 doi: 10.1037/0278-6133.26.2.136 – volume: 57 start-page: 381 issue: 5 year: 2010 ident: cit0011 publication-title: [Nihon Koshu Eisei Zasshi] Jpn J Public Health – ident: cit0015 doi: 10.1098/rsif.2016.0820 – ident: cit0019 doi: 10.1186/s12962-018-0163-2 – ident: cit0024 doi: 10.1016/j.ebiom.2016.08.042 – ident: cit0025 doi: 10.1007/s11747-019-00666-6 – ident: cit0004 doi: 10.1016/j.vaccine.2011.10.030 – ident: cit0020 doi: 10.1371/journal.pone.0215125 – ident: cit0001 doi: 10.1002/jmv.25678 – ident: cit0014 doi: 10.1002/9781118548387 – ident: cit0022 – ident: cit0010 doi: 10.1086/341419 – volume: 17 start-page: 273 issue: 2 year: 2018 ident: cit0017 publication-title: IIUM Med J Malaysia – ident: cit0007 doi: 10.1007/s10198-008-0124-3 – ident: cit0008 doi: 10.3390/ijerph7030853 |
| SSID | ssj0000702466 |
| Score | 2.661442 |
| Snippet | The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical COVID-19... Background The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical... Background The development of a vaccine against SARS-CoV-2 infection is on the way. To prepare for public availability, the acceptability of a hypothetical... |
| SourceID | doaj pubmedcentral proquest pubmed crossref informaworld |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2204 |
| SubjectTerms | Adolescent Adult Aged Betacoronavirus - immunology Coronavirus Infections - economics Coronavirus Infections - prevention & control Coronavirus Infections - psychology COVID-19 COVID-19 vaccination COVID-19 Vaccines Cross-Sectional Studies Female health belief model Health Care Surveys Health Expenditures Humans intention Malaysia Malaysia - epidemiology Male Middle Aged Models, Psychological Pandemics - prevention & control Patient Acceptance of Health Care - statistics & numerical data Pneumonia, Viral - prevention & control Research Paper SARS-CoV-2 Socioeconomic Factors Vaccination - economics Vaccination - psychology Viral Vaccines - economics willingness to pay Young Adult |
| Title | The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay |
| URI | https://www.tandfonline.com/doi/abs/10.1080/21645515.2020.1790279 https://www.ncbi.nlm.nih.gov/pubmed/32730103 https://www.proquest.com/docview/2429783185 https://pubmed.ncbi.nlm.nih.gov/PMC7553708 https://doaj.org/article/a100fc69d47b4dd2bd268fa4771c118d |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgEhIXRPkMlMpIXEPtOInjI22pChLlQlFvlmN7RCWUXbVZaP99Z-zsardC2gtXx4liz3jmjcd-w9gHBMUVQBClNKDLWmpZdq2LJcTeA4YDQXjah_x21p6e118vmou1Ul90JizTA-eJO3BSCPCtCbXu6xCqPlRtB67WWnoEx4GsL_q8tWAq2WCNviclKiuMB0qEBc3y-k4nDqiNmjA8rLBJG4zNzIZjSvz999hL_4VB7x-lXPNNJ0_ZkwlU8k95MLvsQRyesUe5zOTtc3aDusAX15HPgCPe4_nuI-8j4k_gqRYOH2fcpfwvn19R7oaK8FB_opMYRnqMpjGiaUxfOPr-88sxTjz_4zxl5rkbAv97mfi9yXZS_7m7fcHOTz7_ODotp4oLpUfgM-KSaYMRvg0A3iQsqRRONYRe-o52RyQ0AsXu2s6j3w_BtX0tpTfgQEcT1Eu2M8yG-JpxABdlNH0bOsoVRodQ3mvltW981XS6YPVyuq2f6MipKsZvKyfW0qWULEnJTlIq2MfVa_PMx7HthUOS5aoz0WmnBlQyOymZ3aZkBTPrmmDHtJsCufSJVVt-4P1SbSwuXcrHuCHOFtcW0RFtvCFiKtirrEar31QVmV6hCqY3FGxjHJtPhstfiR5cN43SonvzPwb-lj2mseRDdXtsZ7xaxHeIwsZ-nz1U4mw_Lbs761MqcA |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCMGF9yM8jcQ1S5yHHR-hUG2hXS4t6s1y_IAKlKy2WaD8embsZLW7AvXQa2xHfozH34zH3xDyGkBx7r3NUia9SEsmWFpz7VLvGuPBHLCZQT_k4YxPj8uPJ9XJ2lsYDKtEG9pHooigq3FzozN6DIl7kwPGh5O-AvMuh09Cgm0lr5JrleQCsxgU2WzlZwGRzuOVJbZKsdn4kOd_f9o4ogKT_xaP6b_Q6HZQ5doptXebmHF8MTjl-2TZNxPzZ4v68XITcIfcGkAsfRul7i654tp75HpMa3l-n_wG2aPLM0c7TwFf0vjWkjYO8K6nIfcO7Tuqw30znS_wrgiT_mB9pK9oeywGVexAFYc_7H7-sv8eFpr-1AYjASh0nf46DXziqKux_lyfPyDHex-OdqfpkOEhNQC0etii3MrMcOu9kQG7FoUuhbcNMzV6Y5ivMhAzzWsDOMNazZuSMSO99sJJWzwkO23XuseEeq8dc7Lhtsa7SafBdDCiMMJUJq9qkZByXFRlBvpzzMLxQ7GBJXWcVIWTqoZJTchk1Wwe-T8uavAOJWZVGem7w4du8VUN2kBplmXecGlL0ZTW5o3Nee1h5IIZsPhsQuS6vKk-eG98TLWiigs68GoUTgWqAu9_dOu65ZkCNIaOPkBoCXkUhXXVzSJHVZ8VCREbYrwxjs2S9vRboCMXVVWIrH5yiT6_JDemR4cH6mB_9ukpuYlFMY7vGdnpF0v3HIBf37wIO_sv-KVJhA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagCNQLb0p4GolrljgPOz5Cy6rlsXCgiJvl-AEVKFntZoHy65mxk1V3Beqh19iO_BiPvxmPvyHkOYDi3HubpUx6kZZMsLTm2qXeNcaDOWAzg37I9zN-eFy--VKN0YTLIawSbWgfiSKCrsbNPbd-jIh7kQPEh4O-Ausuh09CgmklL5MrHMnD8RVHNlu7WUCi83hjia1SbDa-4_nfnzZOqEDkv0Vj-i8wuh1TeeaQmt4gzTi8GJvyfbLqm4n5s8X8eKHx3yTXBwhLX0aZu0UuufY2uRqTWp7eIb9B8uhq6WjnKaBLGl9a0sYB2vU0ZN6hfUd1uG2m8wXeFGHKH6yP5BVtj8WgiB0o4vCH_Q-fjw5gmelPbTAOgELP6a-TwCaOmhrrz_XpXXI8ff1p_zAd8jukBmBWDxuUW5kZbr03MiDXotCl8LZhpkZfDPNVBkKmeW0AZVireVMyZqTXXjhpi3tkp-1ad59Q77VjTjbc1ngz6TQYDkYURpjK5FUtElKOa6rMQH6OOTh-KDZwpI6TqnBS1TCpCZmsm80j-8d5DV6hwKwrI3l3-NAtvqpBFyjNsswbLm0pmtLavLE5rz2MXDAD9p5NiDwrbqoPvhsfE62o4pwOPBtlU4GiwNsf3bputVSAxdDNB_gsIXtRVtfdLHJU9FmRELEhxRvj2CxpT74FMnJRVYXI6gcX6PNTcu3jwVS9O5q9fUh2sSQG8T0iO_1i5R4D6uubJ2Ff_wWnPkgo |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+use+of+the+health+belief+model+to+assess+predictors+of+intent+to+receive+the+COVID-19+vaccine+and+willingness+to+pay&rft.jtitle=Human+vaccines+%26+immunotherapeutics&rft.au=Wong%2C+Li+Ping&rft.au=Alias%2C+Haridah&rft.au=Wong%2C+Pooi-Fong&rft.au=Lee%2C+Hai+Yen&rft.date=2020-09-01&rft.pub=Taylor+%26+Francis&rft.issn=2164-5515&rft.eissn=2164-554X&rft.volume=16&rft.issue=9&rft.spage=2204&rft.epage=2214&rft_id=info:doi/10.1080%2F21645515.2020.1790279&rft_id=info%3Apmid%2F32730103&rft.externalDocID=PMC7553708 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2164-5515&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2164-5515&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2164-5515&client=summon |